Article Text

Download PDFPDF
Identification of trimethylamine N-oxide (TMAO)-producer phenotype is interesting, but is it helpful?
  1. Arduino Arduini1,
  2. Victor A Zammit2,
  3. Mario Bonomini3
  1. 1 R&D Department, CoreQuest Sagl, Manno, Switzerland
  2. 2 Translational Medicine, Warwick Medical School, University of Warwick, Coventry, UK
  3. 3 Unit of Nephrology and Dialysis, Department of Medicine and Aging Sciences, University of “G. d’Annunzio”, Chieti, Italy
  1. Correspondence to Dr Arduino Arduini, R&D Department, CoreQuest Sagl, Manno 6928, Switzerland; a.arduini{at}

Statistics from

We read with great interest the paper by Wu et al 1 reporting on the development of a carnitine challenge test to facilitate the identification of trimethylamine N-oxide (TMAO)-producer phenotype and host-diet-gut dysbiosis. Such a test assumes that, according to a partial reading of the literature, TMAO plays a key role in cardiovascular disease (CVD). Accordingly, the authors assert the implied importance of the potential for adverse CVD-inducing actions of compounds generating TMAO subsequent to the action of gut microbiota on dietary carnitine. However, a more objective reading of the literature shows that the biomedical community is still debating the potential involvement of TMAO in inducing …

View Full Text


  • Contributors The authors have equally contributed to the paper.

  • Competing interests AA is an employee of CoreQuest Sagl. Other authors have no competing interests to declare.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.